| BUSINESS STRATEGY |
sales from generic APIs are only about a quarter of those from exclusive synthesis. "We do not develop generic APIs and then go out and sell. "We develop generics only if a customer is interested." Furthermore, because the company is small, it cannot take on generic APIs for blockbuster drugs. So it goes for low-volume products. finds no reason for conflicts of interest to arise when API manufacturers work with both innovator and generic drug producers. "If you are always fair and clear to everybody, there is no conflict," he says. The situation hasn't come up, but if a generic company inquires about an API that is being supplied to an innovator for a drug that has come off patent. "we will respect the wishes of our longtime partner. If the innovator says no, we will tell the generic company, 'Sorry.' "
|